… ProQR Announces Publication on QR-110 for Leber’s Congenital … LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Adamson, Ph.D., senior vice president of ophthalmology for ProQR. “The ongoing clinical trial of QR-110 in patients with …
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company’
… ProQR Announces Positive Results from Clinical Trial of … trials,” said Aniz Girach, MD, Chief Medical Officer of ProQR, “With just a single dose, QR-421a demonstrated … to address this significant unmet need,” said Benjamin R. Yerxa, PhD, Chief Executive Officer at the Foundation …
… ProQR Announces the Grant of two Key Patents, protecting … QR-010 for Cystic Fibrosis in the US and EU Key Updates ProQR received notice of grant for 2 key patents protecting … General Counsel and Chief Corporate Development Officer of ProQR. “We pursue a very aggressive patent strategy as our 16 …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …
… ProQR Strengthens its Scientific Advisory Board with the … SAB. Science is at the core of everything we do at ProQR, and with this group as our key advisors we can be more … of success that will be invaluable as we advance our R&D programs and our broader RNA technologies, including the …